1715-33-9

• 常用中文名：氢化泼尼松琥珀酸钠
• 常用英文名：Predonine
• CAS号：1715-33-9
• 分子式：C₂₅H₃₁NaO₈
• 分子量：482.499
• 相关类别： 原料药 激素及调节内分泌功能类药 肾上腺皮质激素类药
• 发布时间：2018-03-28 08:00:00
• 更新时间：2026-07-16 08:05:52
• 【用途一】
  用作医药中间体

名称

• 中文名: 泼尼松龙琥珀酸钠
• 英文名: Prednisolone 21-hemisuccinate sodium salt
• 中文别名: 氢泼琥钠; 泼尼松龙21-半丁二酸钠; 泼尼松龙21-半丁二酸钠中间体; 波尼松龙21-半琥珀酸钠盐; 强的松龙琥珀酸钠盐
• 英文别名: Solu-Decortin; meticortelane; 11BETA,17ALPHA,21-TRIHYDROXY-1,4-PREGNADIENE-3,20-DIONE 21-HEMISUCCINATE SODIUM SALT; Methyprednisolone sodium succinate; MFCD00070045; EINECS 216-995-1; Prednisolone 21-hemisuccinate sodium; 1,4-PREGNADIEN-11-BETA, 17,21-TRIOL-3,20-DIONE 21-HEMISUCCINATE SODIUM SALT; 1, 4-PREGNADIEN-11β, 17, 21-TRIOL-3, 20-DIONE 21-HEMISUCCINATE SODIUM SALT; PREDNISOLONE 21-HEMISUCCINATE SODIUM SALT; Predonisolone sodium hemisuccinate; Sodium 4-{[(11β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy}-4-oxobutanoate; Pregna-1,4-diene-3,20-dione, 21-(3-cboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11beta); prednisolonesodiumhemisuccinate; Pregna-1,4-diene-3,20-dione, 11b,17,21-trihydroxy-, 21-succinate, monosodium salt (6CI); Prednisolone sodium succinate //BP; Butanedioic acid, mono[(11β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl] ester, sodium salt (1:1); (11b)-21-(3-Cboxy-1-oxopropoxy)-11,17-dihydroxypregna-1,4-diene-3,20-dione monosodium salt; Sodium prednisolone 21-hemisuccinate; Di-Adreson F-aquosum; Prednisolone 21-succinate sodium salt; Solu-Delta-Cortef; PREDNISOLONE SODIUM SUCCINATE; 4-(2-((10R,11S,13S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-4-oxobutanoic acid; Prednisolone sodium succinate (TN); PREDNISOLONE HEMISUCCINATE, SODIUM SALT; Prednisolone 21-succinate sodium; 11β,17-Dihydroxy-21-[(3-sodiooxycbonyl-1-oxopropyl)oxy]pregna-1,4-diene-3,20-dione; 11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-(Sodium Succinate); 3,20-Dioxo-1,4-pregnadiene-11β,17,21-triol 21-(4-sodiooxy-4-oxobutyrate); 4-diene-3,20-dione,11-beta,17,21-trihydroxy-pregna-21-(hydrogensuccinate); Meticortelane; D1-HYDROCORTISONE 21-HEMISUCCINATE SODIUM SALT; Meticortelone, soluble; butanedioic acid, mono[(11β)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl] ester, monosodium salt; Pregna-1,4-diene-3,20-dione, 21-(3-cboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11b)- (9CI); Pregna-1,4-diene-3,20-dione, 11b,17,21-trihydroxy-, 21-(hydrogen succinate), monosodium salt (7CI, 8CI); METICORTELONE; 11β,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-(sodium succinate); Solu-Decortin H; Prednisolone sodium succinate; Prednisolone Succinate Sodium Salt; prednisolone21-succinatesodium; 1-Hydrocortisone 21-Hemisuccinate Sodium Salt; Meticotelone Soluble; predoninesoluble; DELTA1-HYDROCORTISONE 21-HEMISUCCINATE SODIUM SALT; prednisolone21-sodiumsuccinate; 1,4-Pregnadiene-11β,17,21-Triol-3,20-Dione 21-Hemisuccinate Sodium Salt; Pregna-1,4-diene-3,20-dione, 21-(3-cboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11); Beflubutamid Impurity 6 (Tebutam); prednisolone sodium succinate for injection; 1,4-PREGNADIENE-11BETA,17,21-TRIOL-3,20-DIONE 21-HEMISUCCINATE SODIUM SALT; Succinic acid, 21-monoester with 11b,17,21-trihydroxypregna-1,4-diene-3,20-dione, monosodium salt (8CI); solu-decortin

物化性质

• 沸点: 689.8ºC at 760mmHg
• 分子式: C₂₅H₃₁NaO₈
• 分子量: 482.499
• 闪点: 233.5ºC
• 精确质量: 482.191650
• PSA: 141.03000
• LogP: 0.63860
• 外观性状: powder | white
• 蒸汽压: 5.08E-22mmHg at 25°C
• 储存条件:

  -20°C密封储存

• 稳定性:

  常温常压下稳定

• 计算化学:

  1、 氢键供体数量：3

  2、 氢键受体数量：8

  3、 可旋转化学键数量：7

  4、 互变异构体数量：6

  5、 拓扑分子极性表面积（TPSA）：138

  6、 重原子数量：34

  7、 表面电荷：1

  8、 复杂度：950

  9、 同位素原子数量：0

  10、 确定原子立构中心数量：7

  11、 不确定原子立构中心数量：0

  12、 确定化学键立构中心数量：0

  13、 不确定化学键立构中心数量：0

  14、 共价键单元数量：2

• 更多:

  1. 性状：白色粉末。

  2. 密度（g/mL,25/4℃）： 未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：未确定

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）： 未确定

  7. 折射率： 未确定

  8. 闪点（ºC）： 未确定

  9. 比旋光度（º）： 未确定

  10. 自燃点或引燃温度（ºC）： 未确定

  11. 蒸气压（kPa,25ºC）： 未确定

  12. 饱和蒸气压（kPa,60ºC）： 未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）： 未确定

  15. 临界压力（KPa）： 未确定

  16. 油水（辛醇/水）分配系数的对数值： 未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）： 未确定

  19. 溶解性：未确定

毒性和生态

毒理学数据: 急性毒性：小鼠静脉注射LD50： 770mg/kg；大鼠LD50： 1125 mg/kg CHEMICAL IDENTIFICATION RTECS NUMBER : TU4153500 CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-(hydrogen succinate), monosodium salt CAS REGISTRY NUMBER : 1715-33-9 LAST UPDATED : 198910 DATA ITEMS CITED : 5 MOLECULAR FORMULA : C25-H31-O8.Na MOLECULAR WEIGHT : 482.55 WISWESSER LINE NOTATION : L E5 B666 OV AHTTT&J A1 CQ E1 FV1OV2VO FQ &-NA- HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 770 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : PCJOAU Pharmaceutical Chemistry Journal (English Translation). Translation of KHFZAN. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No.1- 1967- Volume(issue)/page/year: 16,63,1982 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1125 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : PCJOAU Pharmaceutical Chemistry Journal (English Translation). Translation of KHFZAN. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No.1- 1967- Volume(issue)/page/year: 16,63,1982 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 96 mg/kg SEX/DURATION : female 11 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 13,245,1973 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 96 mg/kg SEX/DURATION : female 11-14 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) REFERENCE : SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 13,245,1973 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 96 mg/kg SEX/DURATION : female 11-14 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) REFERENCE : SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 13,245,1973

安全

• 符号: GHS07, GHS08
• 信号词: Warning
• 危害声明: H302-H351
• 警示性声明: P281
• 个人防护装备: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): Xn: Harmful;
• 风险声明 (欧洲): R22
• 安全声明 (欧洲): S22-S36
• 危险品运输编码: NONH for all modes of transport
• WGK德国: 3
• RTECS号: TU4153500